HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA campus plan

This article was originally published in The Rose Sheet

Executive Summary

Completion of offices for the Center for Food Safety and Applied Nutrition at an as-yet-undetermined site in Prince George's County is expected in 2001 under Phase 2 of the FDA campus project. The campus will also house the Center for Veterinary Medicine. The first phase is the completion of the Center for Drug Evaluation and Research at the Montgomery County campus, which is likely to be located in Clarksburg, MD along with the Office of Regulatory Affairs and centers for biologics and medical devices. In Phase 3, the Center for Medical Devices and Radiological Health facilities are slated to be finished in April 2001. Phase 4 will focus on completing offices and labs for the Center for Biologics Evaluation and Research in April 2002. In the final phase (5), the Office of the Commissioner is scheduled to be established in April 2003. The total projected cost of consolidating FDA is $890 mil
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS001117

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel